PEAK1
Summary: This gene encodes a non-receptor tyrosine kinase that is a member of the new kinase family three (NFK3) family. In migrating cells, the encoded protein is associated with the actin cytoskeleton and focal adhesions and promotes developing focal adhesion elongation. This protein may play a role in the regulation of cell migration, proliferation and cancer metastasis. [provided by RefSeq, Mar 2014].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| pseudopodium enriched atypical kinase 1 | MIM:614248 | Ensembl:ENSG00000173517 | HGNC:HGNC:29431 | PA166123722 | 15q24.3 |
GO terms in PEAK1
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IBA | GO:0006468 | protein phosphorylation |
| BP | IDA | GO:0016477 | cell migration |
| BP | IMP | GO:0016477 | cell migration |
| BP | IEA | GO:0018108 | peptidyl-tyrosine phosphorylation |
| BP | IDA | GO:0034446 | substrate adhesion-dependent cell spreading |
| BP | IDA | GO:0046777 | protein autophosphorylation |
| BP | IMP | GO:0048041 | focal adhesion assembly |
| BP | IDA | GO:0051893 | regulation of focal adhesion assembly |
| CC | IEA | GO:0005737 | cytoplasm |
| CC | IBA | GO:0005925 | focal adhesion |
| CC | IDA | GO:0005925 | focal adhesion |
| CC | IBA | GO:0015629 | actin cytoskeleton |
| CC | IDA | GO:0015629 | actin cytoskeleton |
| MF | IBA | GO:0004672 | protein kinase activity |
| MF | IDA | GO:0004715 | non-membrane spanning protein tyrosine kinase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0005524 | ATP binding |
| MF | IDA | GO:0042802 | identical protein binding |
Gene expression in normal tissue: PEAK1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in PEAK1
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD345 | Compound 10b [PMID: 11504634] | 2 |
| iGMDRD424 | Tamatinib | 1 |
| iGMDRD150 | RITA | 16 |
| iGMDRD584 | VER 155008 | 2 |
| iGMDRD512 | nutlin 3 | 3 |
| iGMDRD307 | Manumycin A | 2 |
| iGMDRD154 | NSC23766 | 3 |
| iGMDRD123 | Isoevodiamine | 7 |
| iGMDRD901 | ELCPK | 2 |
| iGMDRD237 | ABT-751 | 5 |
| iGMDRD351 | GW843682X | 3 |
| iGMDRD85 | Ursolic acid | 1 |
| iGMDRD341 | Triacsin c | 3 |
| iGMDRD267 | Oligomycin A | 2 |
| iGMDRD77 | Itraconazole | 2 |
| iGMDRD481 | Dactolisib | 2 |
| iGMDRD6 | AM-580 | 2 |
| iGMDRD705 | Nakiterpiosin | 3 |
| iGMDRD158 | NSC141540 | 5 |
| iGMDRD137 | Indisulam | 7 |
| iGMDRD322 | FK 866 | 2 |
| iGMDRD505 | Pevonedistat | 3 |
| iGMDRD300 | Tozasertib | 1 |
| iGMDRD269 | Purmorphamine | 2 |
| iGMDRD329 | Merck60 | 5 |
| iGMDRD414 | MST-312 | 2 |
| iGMDRD67 | PENFLURIDOL | 3 |
| iGMDRD286 | Nsc 632839 | 5 |
| iGMDRD781 | Sirolimus | 3 |
| iGMDRD494 | Neopeltolide | 2 |
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD579 | PF750 | 2 |
| iGMDRD772 | BRD4770 | 2 |
| iGMDRD1008 | SR-II-138A | 2 |
| iGMDRD420 | Leucascandrolide A | 3 |
| iGMDRD889 | Compound 7d-cis | 3 |
| iGMDRD151 | CHM-1 | 6 |
| iGMDRD126 | Tipifarnib | 2 |
| iGMDRD634 | SCHEMBL2608041 | 8 |
| iGMDRD280 | CYTOCHALASIN B | 1 |
| iGMDRD466 | Chaetocin | 2 |
| iGMDRD297 | Austocystin D | 2 |
| iGMDRD193 | Fqi1 | 1 |
| iGMDRD446 | LY 2183240 | 4 |
| iGMDRD52 | Rotenone | 1 |
| iGMDRD870 | BRD63610 | 5 |
| iGMDRD441 | TW 37 | 2 |
| iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 2 |
| iGMDRD318 | PAC-1 | 6 |
| iGMDRD782 | DC-45-A2 | 3 |
| iGMDRD255 | SB225002 | 3 |
| iGMDRD270 | Ciclosporin | 2 |
| iGMDRD268 | Cerulenin | 2 |
| iGMDRD60 | Quinoclamine | 3 |
| iGMDRD64 | Parbendazole | 2 |
| iGMDRD506 | Fedratinib | 1 |
| iGMDRD577 | BIX01294 | 3 |
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD100 | Zebularine | 2 |
| iGMDRD188 | Piperlongumine | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in PEAK1
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.